IPP Bureau
Bayer launches biotech innovation platform in China
By IPP Bureau - September 17, 2025
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
Pete Pharma and FABRX announce strategic partnership
By IPP Bureau - September 17, 2025
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
GSK to invest $30 billion in R&D, manufacturing in US over next 5 years
By IPP Bureau - September 17, 2025
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
Lilly to build $5 billion manufacturing facility in Virginia
By IPP Bureau - September 17, 2025
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
HCG Manavata launches awareness campaign for prostate cancer
By IPP Bureau - September 17, 2025
Encouraging early detection and breaking the silence around men’s health
ProBioGen to spearhead GMP manufacturing at Berlin’s gene & cell therapy hub
By IPP Bureau - September 17, 2025
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
ZyVet launches first generic treatment for canine urinary incontinence
By IPP Bureau - September 17, 2025
Enveric clears FDA feedback milestone, prepares IND submission for EB-003
By IPP Bureau - September 17, 2025
IND application for EB-003 expected in early 2026
KIMS Hospital Bengaluru commences operations of new hospital in Bengaluru
By IPP Bureau - September 17, 2025
The state-of-the-art facility is a 450-bedded, multi-specialty tertiary care hospital,
FDA approves Lupin’s Lenalidomide capsules
By IPP Bureau - September 17, 2025
Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma
Biocon Biologics receives FDA approval for Bosaya and Aukelso biosimilars
By IPP Bureau - September 17, 2025
Novo Nordisk's oral semaglutide gets EU approval for heart related treatment of type 2 diabet
By IPP Bureau - September 16, 2025
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Alembic Pharmaceuticals receives EIR for API - I and API - II facility located at Panelav
By IPP Bureau - September 16, 2025
The inspection was carried out between May 26, 2025 and May 31, 2025
CIDSCON 2025 emphasized a multi-faceted approach to tackle AMR
By IPP Bureau - September 16, 2025
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
Syensqo introduces medical-grade Amodel PPA for medical devicess
By IPP Bureau - September 16, 2025
A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies
